Bronchoreversibility Test in Asthmatic Children and Correlation With Diagnostic Criteria Proposed by the GINA Guidelines

Pediatric Asthma Clinical Trial

— VERI-VEMS  

Official title:

A Retrospective Study to Verify FEV1 Reversibility Criteria Proposed by the GINA Guidelines, in Asthmatic Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03814018
• Other study ID #: RECHMPL19_0007
• Status: Completed
• Start date: February 1, 2019
• Est. completion date: October 30, 2019

Study information

• Verified date: January 2019
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Since 2015, GINA (Global INitiative on Asthma) guidelines were modified and adapted to better fit the pediatric population. Asthma diagnosis is mainly based on the results of PFT (Pulmonary Function Tests) and broncho-reversibility test in adult. GINA guidelines modified the requirements to reach a diagnosis of Asthma in children, based on the reversibility test. GINA guideline propose an increase of 12% of the FEV1 is considered as the diagnostic criterium for asthma in pediatrics.

Nevertheless, in clinical practice, most physicians base their diagnosis of asthma in children on the clinical signs presented by the patient and on the efficacy of the prescribed therapy. Also, the spirometric criterium is not sufficiently corroborated by clinical studies. No research has ever looked for the results of bronchoreversibility test in patients receiving a clinical diagnosis of asthma. For this reason, in children with a clinical diagnosis of asthma, the investigators want to look for the results of the bronchoreversibility test and validate that an increase of 12% of the FEV1 correlate with a physician-driven diagnosis of asthma in pediatrics. For further analysis the investigatorswill evaluate also the reversibility of small airways (FEF25-75) and the z-score of the results of the PFT in these children.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 600
• Est. completion date: October 30, 2019
• Est. primary completion date: June 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 18 Years

Eligibility

Inclusion criteria:

• Children aged between 5 and 18 years

• Children with a diagnosis of asthma undergoing a PFT and a bronchoreversibility test on the day of the diagnosis

• Children evaluated at the University Hospital of Montpellier (France), or at the Pediatric Allergy Unit of the University Hospital of Pavia (Italy)

Exclusion criteria:

• Children not able to perform a PFT

• Children taking drugs that could affect the results of a PFT

• Children included in other trials that don't allow them to be included in the present one

Related Conditions & MeSH terms

• Asthma
• Pediatric Asthma

Locations

Country	Name	City	State
France	Uhmontpellier	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	value of FEV1 increase	Positive predictive value of FEV1 increase (%) in asthmatic children after bronchodilation test	1 day
Primary	value of FEF 25-75	Positive predictive value of FEF 25-75 increase (%) in asthmatic children after bronchodilation test	1 day